PriceTargets.com logo

Amryt Pharma - AMYT Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 143 As of 01/10/2022 01:00 AM ET
▼ -19 (-11.73%)

This chart shows the closing price for AMYT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Amryt Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMYT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMYT

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Amryt Pharma in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 143.

This chart shows the closing price for AMYT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Amryt Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/29/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/4/2022Shore CapitalReiterated RatingHouse Stock
6/3/2021Shore CapitalReiterated RatingHouse Stock
5/5/2021Shore CapitalReiterated RatingHouse Stock
3/3/2021Shore CapitalReiterated RatingHouse Stock
12/17/2020Shore CapitalReiterated RatingHouse Stock
10/29/2020Shore CapitalReiterated RatingHouse Stock
5/18/2020Berenberg BankReiterated RatingHouse Stock
5/11/2020Shore CapitalReiterated RatingHold
(Data available from 11/26/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/29/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Amryt Pharma logo
Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: GBX 143
Low: 143
High: 155

50 Day Range

MA: GBX 143
Low: 143
High: 143

52 Week Range

Now: GBX 143
Low: 135
High: 230

Volume

90,726 shs

Average Volume

469,552 shs

Market Capitalization

£457.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Amryt Pharma?

The following Wall Street sell-side analysts have issued reports on Amryt Pharma in the last twelve months:
View the latest analyst ratings for AMYT.

What is the current price target for Amryt Pharma?

0 Wall Street analysts have set twelve-month price targets for Amryt Pharma in the last year. has the lowest price target set, forecasting a price of £100,000 for Amryt Pharma in the next year.
View the latest price targets for AMYT.

What is the current consensus analyst rating for Amryt Pharma?

Amryt Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AMYT.

What other companies compete with Amryt Pharma?

Other companies that are similar to Amryt Pharma include Grainger, Indivior, Standard Life UK Smaller Companies Trust, Ergomed and Bloomsbury Publishing. Learn More about companies similar to Amryt Pharma.

How do I contact Amryt Pharma's investor relations team?

Amryt Pharma's physical mailing address is Ivybridge House, 1 Adam Street, LONDON, WC2N 6LE, United Kingdom. The company's listed phone number is +44-20-34155730. The official website for Amryt Pharma is www.amrytpharma.com. Learn More about contacing Amryt Pharma investor relations.